dm+d

Unassigned

New Medicines

Atherosclerosis

Information

New molecular entity
Resverlogix Corp
Resverlogix Corp

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Jun 18: Resverlogix received confirmation from the US FDA that the phase III BETonMACE study, s likely to support the filing and approval of a New Drug Application (NDA) [11]

Category

BET-protein inhibitor, facilitates endogenous ApoA-I production and raises HDL levels
Atherosclerosis usually manifests in later life, but its early phases are present in teenagers and young adults. [2]
Atherosclerosis
Oral

Evidence based evaluations